EUS-Guided Cyanoacrylate Injection With Balloon-Compression Sclerotherapy Versus Band Ligation for Gastroesophageal Varices: A Randomized Trial
- Journal
- Journal of gastroenterology and hepatology (Q1)
- Published
- 17 September 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Xu Yang, Zhihong Wang, Yuxin Liao, Xuerong Cheng, Derun Kong
- PMID
- 42755133
- DOI
- 10.1111/jgh.70715
Why clinicians should know about it
- Picked for Gastroenterology (top studies of the week, 20 September 2026): Randomized trial of EUS‑CYA + bc‑EIS vs EVL for varices
Abstract
BACKGROUND AND OBJECTIVES: Gastroesophageal varices (GOV) is a life-threatening complication of portal hypertension. Endoscopic ultrasound-guided cyanoacrylate injection (EUS-CYA) improves gastric variceal treatment, but the optimal strategy for concomitant esophageal varices (EV) remains unclear. We compared EUS-CYA combined with balloon-compression endoscopic injection sclerotherapy (bc-EIS) versus EUS-CYA combined with endoscopic variceal ligation (EVL). METHODS: Single-center randomized controlled trial (July 2022-June 2025). Cirrhotic patients with GOV were assigned 1:1 to EUS-CYA + bc-EIS (n = 62) or EUS-CYA + EVL (n = 62). All received EUS-guided "sandwich technique" for gastric varices (GV). Then, bc-EIS (polidocanol under balloon compression for 10 min) or EVL (spiral ligation) was performed for EV. The primary endpoint was combined eradication rate of both GV and EV at 6 months. RESULTS: GV final eradication: 100% in both groups. EV eradication: 100% in the bc-EIS group versus 82.3% in the EVL group (p < 0.001). Fewer sessions needed for bc-EIS (1.4 ± 0.6 vs. 2.1 ± 1.1, p < 0.001). Rebleeding: 9.7% versus 21.0% (p = 0.081). Independent rebleeding risk factors: esophageal variceal diameter > 10 mm (HR = 6.98) and prior bleeding (HR = 4.57). No significant differences in hemostasis (100% both), complications (14.5% vs. 17.7%), or recurrence (0 vs. 3.2%). No severe adverse events. CONCLUSION: EUS-CYA combined with bc-EIS significantly improves esophageal variceal eradication and reduces treatment sessions compared with EUS-CYA + EVL, with comparable safety. TRIAL REGISTRATION: ChiCTR2000039974.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.